Next-generation sequencing of dried blood spot specimens: A novel approach to HIV drug-resistance surveillance

Antiviral Therapy

Volumn 16, Issue 6, 2011, Pages 871-878

  Ji, Hezhao ^a   Li, Yang ^a   Graham, Morag ^a,b   Liang, Ben Binhua ^a   Pilon, Richard ^a   Tyson, Shari ^a   Peters, Geoff ^a   Tyler, Shaun ^a   Merks, Harriet ^a   Bertagnolio, Silvia ^c   Soto Ramirez, Luis ^d   Sandstrom, Paul ^a   Brooks, James ^a  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

^d INSTITUTO NACIONAL DE CIENCIAS MÉDICAS Y NUTRICIÓN SALVADOR ZUBIRÁN   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONSENSUS SEQUENCE; CONTROLLED STUDY; COST CONTROL; DNA SEQUENCE; DRIED BLOOD SPOT; DRUG SURVEILLANCE PROGRAM; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEXICO; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PREVALENCE; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; VIRUS LOAD;

CONSENSUS SEQUENCE; DRUG RESISTANCE, VIRAL; GENOTYPE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MUTATION; PHYLOGENY; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; REPRODUCIBILITY OF RESULTS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY;

EID: 80052943349     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1839     Document Type: Article

References (29)

1. UNAIDS. AIDS epidemic update - December 2009. (Updated December 2009. Accessed 30 June 2010.) Available from http://data.unaids.org/pub/Report/2009/ JC1700-Epi-Update-2009-en.pdf
2. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther 2008; 13 Suppl 2:1-13.
3. Bertagnolio S, Derdelinckx I, Parker M, et al. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy. Antivir Ther 2008; 13 Suppl 2:49-57. (Pubitemid 352019089)
4. Bennett DE, Myatt M, Bertagnolio S, Sutherland D, Gilks CF. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2:25-36. (Pubitemid 352019087)
5. Bertagnolio S, Soto-Ramirez L, Pilon R, et al. HIV-1 drug resistance surveillance using dried whole blood spots. Antivir Ther 2007; 12:107-113. (Pubitemid 46340432)
6. Hamers RL, Smit PW, Stevens W, Schuurman R, Rinke de Wit TF. Dried fluid spots for HIV type-1 viral load and resistance genotyping: a systematic review. Antivir Ther 2009; 14:619-629.
7. Hearps AC, Ryan CE, Morris LM, et al. Stability of dried blood spots for HIV-1 drug resistance analysis. Curr HIV Res 2010; 8:134-140.
8. Johannessen A, Holberg-Petersen M, Lovgaarden G, et al. HIV type-1 drug resistance testing on dried blood spots is feasible and reliable in patients who fail antiretroviral therapy in rural Tanzania. Antivir Ther 2010; 15:1003-1009.
9. Lira R, Valdez-Salazar H, Vazquez-Rosales G, et al. Genotypic testing for HIV-1 drug resistance using dried blood samples. Arch Virol 2010; 155:1117-1125.
10. Masciotra S, Garrido C, Youngpairoj AS, et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in antiretroviral-experienced patients. AIDS 2007; 21:2503-2511. (Pubitemid 350145182)
11. Youngpairoj AS, Masciotra S, Garrido C, et al. HIV-1 drug resistance genotyping from dried blood spots stored for 1 year at 4 degrees C. J Antimicrob Chemother 2008; 61:1217-1220. (Pubitemid 351753584)
12. Margulies M, Egholm M, Altman WE, et al. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005; 437:376-380. (Pubitemid 41613494)
13. Shendure J, Ji H. Next-generation DNA sequencing. Nat Biotechnol 2008; 26:1135-1145.
14. Zhang H, DiBaise JK, Zuccolo A, et al. Human gut microbiota in obesity and after gastric bypass. Proc Natl Acad Sci U S A 2009; 106:2365-2370.
15. Andersson AF, Lindberg M, Jakobsson H, et al. Comparative analysis of human gut microbiota by barcoded pyrosequencing. PLoS ONE 2008; 3:e2836.
16. Simen BB, Simons JF, Hullsiek KH, et al. Low-abundance drug-resistant viral variants in chronically HIV-infected, antiretroviral treatment-naive patients significantly impact treatment outcomes. J Infect Dis 2009; 199:693-701.
17. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW. Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 2007; 17:1195-1201. (Pubitemid 47204863)
18. Hoffmann C, Minkah N, Leipzig J, et al. DNA bar coding and pyrosequencing to identify rare HIV drug resistance mutations. Nucleic Acids Res 2007; 35:e91.
19. Rozera G, Abbate I, Bruselles A, et al. Massively parallel pyrosequencing highlights minority variants in the HIV-1 env quasispecies deriving from lymphomonocyte subpopulations. Retrovirology 2009; 6:15.
20. Ji H, Masse N, Tyler S, et al. HIV drug resistance surveillance using pooled pyrosequencing. PLoS ONE 2010; 5:e9263.
21. Roche. 454 Sequencing Technical Bulletin. Amplicon fusion primer design guidelines for GS FLX Titanium Series Lib-A chemistry. No 013-2009. (Updated August 2009. Accessed November 2009.) Available from http://www.igsb.org/ uploads/pdf/TCB-09013-AmpliconFusionPrimerDesignGuidelines.pdf
22. Roche. 454 Sequencing Technical Bulletin. Using multiplex identifier (MID) adaptors for the GS FLX Titanium chemistry - extended MID set. No. 005-2009. (Updated April 2009. Accessed November 2009.) Available from http://www.eurofinsdna.com/fileadmin/PDFs/product-services/TB-0905-Technical- Bulletin-Roche-MID-Adaptors.pdf
23. Tamura K, Dudley J, Nei M, Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007; 24:1596-1599. (Pubitemid 47236692)
24. Johnson N, Kemp A, Kotz S. Univariate discrete distributions. 3rd ed. Hoboken, New Jersey: John Wiley & Sons 2005; pp. 108-155.
25. Eshleman SH, Guay LA, Wang J, et al. Distinct patterns of emergence and fading of K103N and Y181C in women with subtype A vs. D after single-dose nevirapine: HIVNET 012. J Acquir Immune Defic Syndr 2005; 40:24-29. (Pubitemid 41233200)
26. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatmentnaive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
27. Paredes R, Lalama CM, Ribaudo HJ, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201:662-671.
28. Halvas EK, Wiegand A, Boltz VF, et al. Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment-experienced patients. J Infect Dis 2010; 201:672-680.
29. Metzner KJ, Giulieri SG, Knoepfel SA, et al. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients. Clin Infect Dis 2009; 48:239-247.